Biohaven [BHVN] vs Vera Therapeutics [VERA] Detailed Stock Comparison

Biohaven

NYSE
Loading...

Vera Therapeutics

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 15 vital metrics comparison: Biohaven wins in 0 metrics, Vera Therapeutics wins in 12 metrics, with 3 ties. Vera Therapeutics appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricBiohavenVera TherapeuticsBetter
P/E Ratio (TTM)-1.70-10.96Vera Therapeutics
Price-to-Book Ratio12.434.11Vera Therapeutics
Debt-to-Equity Ratio25.6316.56Vera Therapeutics
PEG Ratio0.04-0.12Vera Therapeutics
EV/EBITDA-1.40-6.13Vera Therapeutics
Profit Margin (TTM)0.00%0.00%Tie
Operating Margin (TTM)0.00%0.00%Tie
Return on Equity-295.94%-54.84%Vera Therapeutics
Return on Assets (TTM)-103.41%-30.24%Vera Therapeutics
Free Cash Flow (TTM)$-586.50M$-135.65MVera Therapeutics
1-Year Return-66.81%-26.20%Vera Therapeutics
Enterprise Value$1.30B$1.44BVera Therapeutics
Revenue per Share (TTM)$0$0Tie
Earnings per Share (Diluted)$-7.46$-3.59Vera Therapeutics
Beta (Stock Volatility)3.451.23Vera Therapeutics
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Biohaven vs Vera Therapeutics Stock Performance Analysis

Loading Price Chart...

Biohaven
Vera Therapeutics
Biohaven Stock Overview | Vera Therapeutics Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biohaven1.93%5.40%-2.47%8.07%-23.07%-57.59%
Vera Therapeutics3.25%6.88%31.27%25.58%32.54%-28.58%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biohaven-66.81%22.65%116.58%-11.73%-11.73%-11.73%
Vera Therapeutics-26.20%51.00%162.09%162.09%162.09%162.09%

News Based Sentiment: Biohaven vs Vera Therapeutics

Biohaven

News based Sentiment: POSITIVE

The month of October 2025 brought continued positive signals for Biohaven Ltd. (BHVN), with analysts reaffirming a "Strong Buy" rating and a substantial price target upside. While the share price increase was modest, the overall sentiment suggests a favorable investment outlook.

View Biohaven News Sentiment Analysis

Vera Therapeutics

News based Sentiment: MIXED

October was a month of contrasts for Vera Therapeutics, with significant institutional investment offset by a disappointing earnings report. While analyst sentiment remains generally positive, the earnings miss introduces uncertainty and necessitates a cautious outlook. The combination of these factors makes this a noteworthy month for investors.

View Vera Therapeutics News Sentiment Analysis

Performance & Financial Health Analysis: Biohaven vs Vera Therapeutics

MetricBHVNVERA
Market Information
Market Cap i$1.69B$1.98B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i2,276,9491,529,620
90 Day Avg. Volume i2,397,8401,741,295
Last Close$15.81$30.14
52 Week Range$12.79 - $55.70$18.53 - $51.61
% from 52W High-71.62%-41.60%
All-Time High$67.86 (Jun 03, 2019)$51.61 (Nov 11, 2024)
% from All-Time High-76.70%-41.60%
Growth Metrics
Quarterly Revenue GrowthN/AN/A
Quarterly Earnings GrowthN/AN/A
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i0.00%0.00%
Return on Equity (TTM) i-2.96%-0.55%
Debt to Equity (MRQ) i25.6316.56
Cash & Liquidity
Book Value per Share (MRQ)$1.27$7.34
Cash per Share (MRQ)$3.83$8.72
Operating Cash Flow (TTM) i$-645,078,016$-185,271,008
Levered Free Cash Flow (TTM) i$-508,353,632$-111,946,496
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Biohaven vs Vera Therapeutics

MetricBHVNVERA
Price Ratios
P/E Ratio (TTM) i-1.70-10.96
Forward P/E i-2.50-9.69
PEG Ratio i0.04-0.12
Price to Sales (TTM) iN/AN/A
Price to Book (MRQ) i12.434.11
Market Capitalization
Market Capitalization i$1.69B$1.98B
Enterprise Value i$1.30B$1.44B
Enterprise Value Metrics
Enterprise to Revenue iN/AN/A
Enterprise to EBITDA i-1.40-6.13
Risk & Other Metrics
Beta i3.451.23
Book Value per Share (MRQ) i$1.27$7.34

Financial Statements Comparison: Biohaven vs Vera Therapeutics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)BHVNVERA
Revenue/Sales i$0$0
Cost of Goods Sold iN/AN/A
Gross Profit iN/AN/A
Research & Development i$187.58M$41.28M
Operating Income (EBIT) i$-221.56M$-57.19M
EBITDA i$-219.32M$-49.82M
Pre-Tax Income i$-221.07M$-51.69M
Income Tax i$609,000N/A
Net Income (Profit) i$-221.68M$-51.69M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)BHVNVERA
Cash & Equivalents i$98.42M$55.09M
Total Current Assets i$382.76M$606.08M
Total Current Liabilities i$164.03M$21.89M
Long-Term Debt i$30.80M$53.27M
Total Shareholders Equity i$259.50M$535.00M
Retained Earnings i$-1.57B$-512.94M
Property, Plant & Equipment i$36.78M$1.06M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)BHVNVERA
Operating Cash Flow i$-164.28M$-41.22M
Capital Expenditures i$-461,000$-187,000
Free Cash Flow i$-165.59M$-54.59M
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBHVNVERA
Shares Short i13.19M9.36M
Short Ratio i6.204.91
Short % of Float i0.14%0.17%
Average Daily Volume (10 Day) i2,276,9491,529,620
Average Daily Volume (90 Day) i2,397,8401,741,295
Shares Outstanding i101.22M63.56M
Float Shares i88.38M44.83M
% Held by Insiders i0.12%0.01%
% Held by Institutions i0.83%1.10%

Dividend Analysis & Yield Comparison: Biohaven vs Vera Therapeutics

MetricBHVNVERA
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A